Literature DB >> 25894623

Outcomes associated with routine systemic antifungal therapy in critically ill patients with Candida colonization.

David Ferreira1, Frederic Grenouillet, Gilles Blasco, Emmanuel Samain, Thierry Hénon, Alain Dussaucy, Laurence Millon, Mariette Mercier, Sebastien Pili-Floury.   

Abstract

PURPOSE: To assess the evolution of patient deep colonization by Candida spp. in a surgical ICU over an 8-year period.
METHODS: This retrospective, observational study included all patients hospitalized for more than 2 days in a surgical and trauma ICU of a university hospital, from 2005 to 2012. Mycological samples were monitored weekly from five sites (oropharyngeal, rectal, gastric, tracheal and urinary). Preemptive fluconazole therapy was started in patients highly colonized with Candida albicans. The evolution in Candida spp. involved in the deep colonization sites distribution over the study period (main outcome measure, trend chi-square and time-series analysis), antifungal consumption, ICU-acquired candidemia and mortality were determined.
RESULTS: Among the 3029 patients with ICU stay >48 h, 2651 had at least one set of mycological sampling. Thirty percent of the 31,171 samples were positive to Candida spp. Caspofungin consumption increased over the years, whereas fluconazole consumption decreased. No trend in C. albicans colonization was observed, after adjusting on colonization risk-factors. A significant increase of acquired C. glabrata colonization was observed, whereas the clearing of C. parapsilosis colonization significantly decreased. No significant shift of colonization to other Candida spp. and mortality was observed.
CONCLUSIONS: Preemptive strategy of antifungal drug prescriptions in highly colonized ICU patients induced an increase in C. glabrata colonization without significant shift of colonization to other Candida spp. in surgical ICU patients. However, the potential detrimental impact of fluconazole on Candida ecology in ICU and/or on Candida susceptibility to antifungal drugs should be considered, and deserves further studies.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25894623     DOI: 10.1007/s00134-015-3791-4

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  38 in total

1.  ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients.

Authors:  O A Cornely; M Bassetti; T Calandra; J Garbino; B J Kullberg; O Lortholary; W Meersseman; M Akova; M C Arendrup; S Arikan-Akdagli; J Bille; E Castagnola; M Cuenca-Estrella; J P Donnelly; A H Groll; R Herbrecht; W W Hope; H E Jensen; C Lass-Flörl; G Petrikkos; M D Richardson; E Roilides; P E Verweij; C Viscoli; A J Ullmann
Journal:  Clin Microbiol Infect       Date:  2012-12       Impact factor: 8.067

2.  Candida colonization of respiratory tract: to treat or not to treat, will we ever get an answer?

Authors:  Gennaro De Pascale; Massimo Antonelli
Journal:  Intensive Care Med       Date:  2014-07-01       Impact factor: 17.440

Review 3.  Resistance of Candida spp. to antifungal drugs in the ICU: where are we now?

Authors:  Danièle Maubon; Cécile Garnaud; Thierry Calandra; Dominique Sanglard; Muriel Cornet
Journal:  Intensive Care Med       Date:  2014-08-05       Impact factor: 17.440

4.  Diagnostic issues, clinical characteristics, and outcomes for patients with fungemia.

Authors:  Maiken Cavling Arendrup; Sofia Sulim; Anette Holm; Lene Nielsen; Susanne Dam Nielsen; Jenny Dahl Knudsen; Niels Erik Drenck; Jens Jørgen Christensen; Helle Krogh Johansen
Journal:  J Clin Microbiol       Date:  2011-06-29       Impact factor: 5.948

5.  Impact of therapeutic strategies on the prognosis of candidemia in the ICU.

Authors:  Mireia Puig-Asensio; Javier Pemán; Rafael Zaragoza; José Garnacho-Montero; Estrella Martín-Mazuelos; Manuel Cuenca-Estrella; Benito Almirante
Journal:  Crit Care Med       Date:  2014-06       Impact factor: 7.598

6.  MSG-01: A randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting.

Authors:  Luis Ostrosky-Zeichner; Shmuel Shoham; Jose Vazquez; Annette Reboli; Robert Betts; Michelle A Barron; Mindy Schuster; Marc A Judson; Sanjay G Revankar; Juan Pablo Caeiro; Julie E Mangino; David Mushatt; Roger Bedimo; Alison Freifeld; Minh Hong Nguyen; Carol A Kauffman; William E Dismukes; Andrew O Westfall; Jeanna Beth Deerman; Craig Wood; Jack D Sobel; Peter G Pappas
Journal:  Clin Infect Dis       Date:  2014-02-18       Impact factor: 9.079

Review 7.  Candida colonization index and subsequent infection in critically ill surgical patients: 20 years later.

Authors:  Philippe Eggimann; Didier Pittet
Journal:  Intensive Care Med       Date:  2014-06-17       Impact factor: 17.440

8.  Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial.

Authors:  Mindy G Schuster; John E Edwards; Jack D Sobel; Rabih O Darouiche; Adolf W Karchmer; Susan Hadley; Gus Slotman; Helene Panzer; Pinaki Biswas; John H Rex
Journal:  Ann Intern Med       Date:  2008-07-15       Impact factor: 25.391

9.  Investigation of the sequence of colonization and candidemia in nonneutropenic patients.

Authors:  A Voss; R J Hollis; M A Pfaller; R P Wenzel; B N Doebbeling
Journal:  J Clin Microbiol       Date:  1994-04       Impact factor: 5.948

Review 10.  Candidemia in intensive care unit: a nationwide prospective observational survey (GISIA-3 study) and review of the European literature from 2000 through 2013.

Authors:  M T Montagna; G Lovero; E Borghi; G Amato; S Andreoni; L Campion; G Lo Cascio; G Lombardi; F Luzzaro; E Manso; M Mussap; P Pecile; S Perin; E Tangorra; M Tronci; R Iatta; G Morace
Journal:  Eur Rev Med Pharmacol Sci       Date:  2014       Impact factor: 3.507

View more
  11 in total

1.  Focus on infection and sepsis in intensive care patients.

Authors:  Ignacio Martin-Loeches; Anders Perner
Journal:  Intensive Care Med       Date:  2016-02-09       Impact factor: 17.440

2.  Are prophylactic antifungals in highly colonized patients safe and effective?

Authors:  Matteo Bassetti; Cristobal Leon; Jean Francois Timsit
Journal:  Intensive Care Med       Date:  2015-06-03       Impact factor: 17.440

3.  Antifungal use in intensive care units: another uncertainty that highlights the need for precision medicine.

Authors:  Rima Moghnieh; Zeina A Kanafani; Souha S Kanj
Journal:  J Thorac Dis       Date:  2016-12       Impact factor: 2.895

4.  The most recent concepts for the management of bacterial and fungal infections in ICU.

Authors:  Matteo Bassetti; Garyfallia Poulakou; Marin H Kollef
Journal:  Intensive Care Med       Date:  2018-10-06       Impact factor: 17.440

5.  Impact of selective digestive decontamination on respiratory tract Candida among patients with suspected ventilator-associated pneumonia. A meta-analysis.

Authors:  J C Hurley
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-04-26       Impact factor: 3.267

6.  Biomarker-guided antifungal therapy in patients with suspected invasive candidiasis: Ready for prime time?

Authors:  José-Artur Paiva; Pierre-Emmanuel Charles
Journal:  Intensive Care Med       Date:  2017-11-08       Impact factor: 17.440

7.  Distribution and antifungal susceptibility of yeasts isolates from intensive care unit patients.

Authors:  Vladimír Hrabovský; Victoria Takáčová; Eva Schréterová; Lydia Pastvová; Zuzana Hrabovská; Katarina Čurová; Leonard Siegfried
Journal:  Folia Microbiol (Praha)       Date:  2017-03-30       Impact factor: 2.099

8.  Antimicrobial de-escalation in critically ill patients: a position statement from a task force of the European Society of Intensive Care Medicine (ESICM) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Critically Ill Patients Study Group (ESGCIP).

Authors:  Alexis Tabah; Matteo Bassetti; Marin H Kollef; Jean-Ralph Zahar; José-Artur Paiva; Jean-Francois Timsit; Jason A Roberts; Jeroen Schouten; Helen Giamarellou; Jordi Rello; Jan De Waele; Andrew F Shorr; Marc Leone; Garyphallia Poulakou; Pieter Depuydt; Jose Garnacho-Montero
Journal:  Intensive Care Med       Date:  2019-11-28       Impact factor: 17.440

9.  Improved in vitro and in vivo Anti-Candida albicans Activity of Cymbopogon nardus Essential Oil by Its Incorporation into a Microemulsion System.

Authors:  Luciani Gaspar de Toledo; Matheus Aparecido Dos Santos Ramos; Patrícia Bento da Silva; Camila Fernanda Rodero; Veridiana de Sá Gomes; Anderson Noronha da Silva; Fernando Rogério Pavan; Isabel Cristiane da Silva; Fernando Bombarda Oda; Danilo Luis Flumignan; André Gonzaga Dos Santos; Marlus Chorilli; Margarete Teresa Gottardo de Almeida; Taís Maria Bauab
Journal:  Int J Nanomedicine       Date:  2020-12-29

Review 10.  Diagnosis and management of invasive candidiasis in the ICU: an updated approach to an old enemy.

Authors:  Thierry Calandra; Jason A Roberts; Massimo Antonelli; Matteo Bassetti; Jean-Louis Vincent
Journal:  Crit Care       Date:  2016-05-27       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.